Clinical trial · Observational
Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer
NCT02257775CI-TRIAL-00031428EVOLUTIONterminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Insufficient number of eligible and interested partients
Summary
Brief summary (as posted)
The objective of this study is to apply Whole-body DW imaging alongside the routine management of patients requiring systemic therapy for metastatic breast cancer to compare the time to progression of individual liver metastases within and between patients following stable disease or partial response to palliative systemic therapy for breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| n/a - observational | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression rate of liver metastases
- timeFrame
- 3 months
- description
- Patients will be monitored by routine CT scans after 3 cycles of cytotoxic/biological therapy or after 3 months of endocrine therapy
Secondary outcomes (4)
- measure
- Progression rate of skeletal metastases
- timeFrame
- 3 months
- description
- Patients will be monitored by routine CT scans after 3 cycles of cytotoxic/biological therapy or after 3 months of endocrine therapy
- measure
- Global and local lesion Apparent Diffusion Coefficient (ADC) distributions of WB-DWI scans within individual patient
- timeFrame
- 3 months
- description
- Patients will be monitored by routine CT scans after 3 cycles of cytotoxic/biological therapy or after 3 months of endocrine therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age over 18 years. * First metastatic breast cancer relapse after treatment for early stage disease * A minimum of 10 evaluable lesions in the liver on routine x-ray CT imaging * Patient prescribed cytotoxic, endocrine or biological therapies * Patient physically and psychologically fit enough to consider sequential WB-- - DWI imaging alongside their standard disease monitoring * Written informed consent Exclusion Criteria: * Diagnosis of other cancer within the last 5 years, other than resected non-melanoma skin cancer or cervical intraepithelial neoplasia * Diagnosis of brain metastases. * Contraindication to magnetic resonance MR imaging
References
Publications (0)
Data not yet available
No reference posted for this study.